[A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova2014PMID: 25176261

Clinical TrialSelank

Plain Language Summary

A clinical comparison of Selank vs. phenazepam (a benzodiazepine) in 60 patients with phobic, anxiety, and somatoform disorders. Selank produced comparable anxiolytic effects plus mild nootropic (cognitive-enhancing) benefit—and its effects lasted a week after the last dose, unlike phenazepam. Establishes Selank as a clinically effective alternative to benzodiazepines with superior cognitive tolerability.

Abstract

Objective. To study the efficacy and tolerability of the new anxyolytic peptide selank in comparison with phenazepam. Material and methods. A comparative study of the anxiolytic effect and tolerability of selank and phenazepam was carried out in 60 patients with phobic-anxiety- and somatoform disorders (F40.2-9, F41.1-9, F45.0-1 by ICD-10) were examined. Results Pronounced anxiolytic and mild nootropic effects of selank were demonstrated. The anxiolytic effect lasted for a week after last receiving the peptide. Selank had a positive impact on the quality of life of the patients. Conclusion. The data obtained in the study extend therapeutic possibilities in the treatment of anxiety disorders.

Authors

Medvedev, V E; Tereshchenko, O N; Israelian, A Iu; Chobanu, I K; Kost, N V; Sokolov, O Iu; Miasoedov, N F